MDL and Mass Tort Financing: How Funders Evaluate Multi-District Litigation

The mechanics of multi-district litigation, bellwether dynamics, and how capital is deployed across mass tort portfolios.

Multi-district litigation (MDL) consolidates large numbers of related federal cases before a single transferee judge for coordinated pretrial proceedings. Created under 28 U.S.C. § 1407, the MDL device manages mass tort litigation involving defective drugs, medical devices, environmental exposures, and consumer products, where thousands or tens of thousands of plaintiffs assert similar claims against common defendants. For litigation finance, MDLs represent a distinct asset class with their own risk and timeline characteristics that differ substantially from single commercial cases.

The bellwether trial process is central to how MDLs resolve and how funders evaluate them. The transferee court selects representative cases for early trials, and the outcomes of those bellwethers signal the strength of the overall litigation and shape global settlement negotiations. A string of strong plaintiff verdicts can drive a defendant toward an aggregate settlement; defense verdicts can collapse the inventory value. Funders model this dynamic carefully, because the value of a mass tort portfolio is highly sensitive to bellwether results and to scientific rulings on general causation.

Mass tort financing is most often structured at the portfolio level rather than case by case. A law firm managing a large inventory of plaintiffs needs capital to fund case acquisition, medical record retrieval, expert development, and the years of carrying costs before resolution. Funders extend capital against the expected aggregate recovery of the inventory, applying concentration limits and diversification analysis. The funder evaluates the firm's docket composition, the strength of the underlying science, the procedural posture of the MDL, and the defendant's settlement history.

Timeline risk is the defining challenge. MDLs routinely take five to seven years from formation to global resolution, and some run far longer. Capital deployed early carries duration risk that compounds the return requirement, while capital deployed near a settlement carries less risk but commands lower multiples. Funders also account for common benefit assessments, lien resolution complexity, and the mechanics of qualified settlement funds, all of which affect the timing and net amount of recovery flowing back to repay the investment.

Criterica Capital underwrites mass tort and MDL portfolios using outcome data drawn from 106M+ court records, including the procedural and outcome history of comparable federal dockets. This lets us assess settlement timing and recovery distribution with more precision than intuition allows. Law firms managing mass tort inventories and funds seeking diversified mass tort exposure can contact our institutional team to discuss portfolio structures.

Discuss your matter with our institutional team.